Biomarin Pharmaceutical
- Country
- ๐จ๐ฆCanada
- Ownership
- -
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- $17.2B
- Website
- http://www.biomarin.com
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT06138327
- Locations
- ๐บ๐ธ
University of Alabama - Department of Urology, Birmingham, Alabama, United States
๐บ๐ธProSciento, Inc., Chula Vista, Florida, United States
๐บ๐ธMedpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
- Conditions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 450
- Registration Number
- NCT05813678
- Locations
- ๐บ๐ธ
University of Texas Southwestern Medical Center, Dallas, Texas, United States
๐บ๐ธMedical College of Wisconsin, Milwaukee, Wisconsin, United States
๐ฎ๐นPoliclinico Sant'orsola Malpighi, Bologna, Italy
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 36
- Registration Number
- NCT05813314
- Locations
- ๐บ๐ธ
Labcorp, Dallas, Texas, United States
A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
- Conditions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 172
- Registration Number
- NCT05768386
- Locations
- ๐บ๐ธ
UCN Hemophilia and Thrombosis Center, Shandon, California, United States
๐ฌ๐งAddenbrooke's Hospital, Hemophilia and Thrombophilia Center, Cambridge, United Kingdom
๐ฌ๐งHammersmith Hospital, Clinical Research Facility, Centre for Translational and Experimental Medicine, London, United Kingdom
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziqยฎ (Pegvaliase) During Pregnancy and Breastfeeding
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 50
- Registration Number
- NCT05579548
- Locations
- ๐ฉ๐ช
Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany
๐ฎ๐นOspedale San Paolo, Milano, Italy
๐บ๐ธSyneos Health, Wilmington, North Carolina, United States
A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 321
- Registration Number
- NCT05580692
- Locations
- ๐ธ๐ฆ
King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
๐ฆ๐ทInstituto de Hematologia y Medicina Clinica Dr. RUben Davoli, Rosario, Argentina
๐ฆ๐ทInstituto Hematologia Arbesu, Godoy Cruz, Mendoza, Argentina
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 55
- Registration Number
- NCT05270837
- Locations
- ๐บ๐ธ
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธPhoenix Children's Hospital, Phoenix, Arizona, United States
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
- Conditions
- Interventions
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 44
- Registration Number
- NCT05121376
- Locations
- ๐บ๐ธ
Optimed Research, LTD, Columbus, Ohio, United States
๐บ๐ธUniversity of California San Diego, San Diego, California, United States
๐บ๐ธMedical Research of Arizona, Scottsdale, Arizona, United States
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 10
- Registration Number
- NCT04684940
- Locations
- ๐จ๐ณ
Kaohsiung Medical University - Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
๐จ๐ณNational Taiwan University Hospital, Taipei, Taiwan
๐ฎ๐ฑChaim Sheba Medical Center, Ramat Gan, Israel
A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A
- Conditions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 186
- Registration Number
- NCT04560933
- Locations
- ๐บ๐ธ
Covance Inc, Madison, Wisconsin, United States